Cesca Therapeutics Inc. to Present at the BIO CEO & Investor Conference on Monday, February 12, 2018

RANCHO CORDOVA, Calif., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. ("Cesca") KOOL a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Chris Xu, Ph.D., chief executive officer, will be presenting at the BIO CEO & Investor Conference on Monday, February 12, 2018 at 2:30pm EST. The conference is being held February 12-13 at the New York Marriott Marquis.

About Cesca Therapeutics Inc.        

Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop an automated, functionally-closed CAR-TXpress platform that addresses cellular manufacturing needs in the immuno-oncology field.

Company Contact:

Cesca Therapeutics Inc.

Wendy Samford

916-858-5191

ir@cescatherapeutics.com

Investor Contact:

Rx Communications

Paula Schwartz

917-322-2216

pschwartz@rxir.com